Disclosures: Kazuaki Chayama – Consulting: Abbvie;

Grant/Research Support: Dainippon Sumitomo, Chugai, Mitsubishi Īanabe, DAIICHI SANKYO, Toray, BMS, MSD; Speaking and Teaching: Chugai, Mitsubishi Īanabe, DAIIcHl SANKYO, KYORIN, Nihon Medi-Physics, BMS, Dainippon Sumitomo, MSD, ASKA, Astellas, AstraZeneca, Eisai, Olympus, GlaxoSmithKline, ZERIA, Bayer, Minophagen, Shinyaku, Takeda, AJINOMOTO, Meiji Seika, Toray The following people have nothing to disclose: Tsunehiro Ochi, Motoi Hashiba, Masafumi Ono, Hideyuki Hyogo, Yukio Ikeda, Kensuke Munekage, Nobuto Okamoto, Shinji Iwasaki, Yuichiro Eguchi, Toshiji Saibara Background/Aims: Gallstone disease and fatty liver are both prevalent diseases in the general populations and share the same risk factors AZD5363 supplier such as obesity and insulin resistance. However, association between gallstone disease and ultrasonographically diagnosed fatty liver has not been completely established. The aim of this study was to characterize the relationship between gallstone

disease and fatty liver in large population. Methods: A cross-sectional study with 24, 050 health check-up subjects was conducted. Gallstone disease was defined as the presence of gallstones on abdominal sonography or previous history of cholecystectomy. Fatty liver was diagnosed on the basis of typical ultrasonographic findings. Subjects positive for hepatitis B or C virus or check details with a history of other forms of hepatitis were excluded. Results: The mean age of the subjects was 48.7 ± 11.1 years and 54.5% were male. The prevalence of gallstone disease was 5.3% (n=1, 280). The prevalence of fatty liver increased with presence of gallstone disease (43.0% vs.31.3%, p <0.001). In the same manner, the prevalence of gallstone disease increased with presence of fatty liver (7.2% vs.4.4%, p <0.001). The gallstone disease was significantly associated with fatty liver after adjusted for age SPTLC1 and sex [odds ratio (OR) 1.50 95%

confidence interval (Cl) 1.331.69]. Multivariate regression analysis after adjustment for body mass index, waist circumference, total cholesterol, triglycerides, HDL cholesterol, HbA1 c, and systolic blood pressure showed that gallstone disease was statistically significantly associated with fatty liver (OR 1.23, 95% CI 1.06-1.42, p=0.007). These association was attenuated, however still statistically significant after adjusting for insulin resistance (OR 1.27 95% Cl 1.04-1.55, p=0.018). Conclusions: Patients with fatty liver have a high prevalence of gallstone disease. Gallstone disease is associated with fatty liver independently of known metabolic risk factors, especially insulin resistance.